Buy BPC-157 Peptide: Match the Mass to the Sequence

Buy BPC-157 peptide and what arrives is a sealed vial of lyophilised powder: a synthetic 15-residue sequence, GEPPPGKPADDAGLV, weighing 10 mg by label. It is not a formulated medicine and there is no approved version of it anywhere in the world.

That makes the purchase unusual. With a licensed drug the identity of the contents is guaranteed by a marketing authorisation and a batch release process. Here it is guaranteed by a document, or it is not guaranteed at all. This page is about reading that document against the molecule it claims to describe, and about what changes when the parcel has to cross a border.

What you are buying when you buy BPC-157 peptide

BPC-157 is a pentadecapeptide: fifteen amino acids, no lipid chain, no non-natural residues, no conjugation. The sequence corresponds to a partial fragment of a protein found in gastric juice, and the material sold is made by solid-phase synthesis rather than extracted from anything. Its identifiers are public: CAS 137525-51-0, formula C62H98N16O22, catalogued on PubChem as CID 9941957.

Those identifiers do the work that a brand name does elsewhere. There is no innovator product to compare a copy against, so identity has to be established from first principles on each lot. What the molecule is proposed to do, and how thin the pharmacokinetic picture is, are covered on our BPC-157 research overview and its mechanism article. This page stays on the vial. Listings written as buy bpc 157 peptide without the hyphen are describing the same compound; the spelling varies, the CAS number does not.

Matching the mass spectrum to the sequence

Identity testing on a synthetic peptide answers one question: does the mass of what is in the vial agree with the mass the sequence predicts. For BPC-157 the target numbers are fixed and public, so a reader can check the certificate arithmetic without a laboratory.

• Average mass of the free peptide, near 1,419.5 g/mol.
• Monoisotopic mass, near 1,418.70 Da.
• Protonated ion on an average-mass basis, near 1,420.5; monoisotopic protonated ion near 1,419.71.
• Doubly charged ion, near 710.4, which is what an electrospray trace often shows.

A certificate that reports an observed mass and does not say which convention it used has left the comparison ambiguous by about a dalton, which sounds trivial and is exactly the margin a truncated or deleted-residue impurity would hide in. The rest of the panel is equally checkable.

The counterion row is the one that changes the price you thought you were paying. A reverse-phase purification run in trifluoroacetic acid delivers the peptide as a TFA salt, and BPC-157 has two sites that protonate under those conditions, the N-terminal amine and its single lysine. At roughly 113 Da per counterion against 1,419.5, the salt fraction can approach 14 percent of the weighed solid. Our cost breakdown works through what that does to a per-milligram figure.

What the label on the glass has to carry

The vial itself is a shorter document and it should agree with the certificate in every particular that appears on both.

• Compound name and, ideally, the CAS number 137525-51-0.
• Net quantity by weight, such as 10 mg, not a volume and not a concentration.
• The lot or batch number, matching the certificate you were shown.
• A research-use statement, and no indication, dose or route of administration.
• Storage conditions for the lyophilised powder.
• The name of the supplier or distributor responsible for the fill.

Two absences matter more than the rest. A vial with no lot number cannot be tied to any analysis, which makes every certificate in the world irrelevant to it. A vial arriving already in solution is a different product with a different stability question, because a peptide in water has a shelf life measured in weeks under refrigeration rather than the longer window a dry cake allows. A 2026 review in Pharmaceutics on the formulation and translational barriers facing BPC-157 treats stability of the material as an open problem rather than a solved one. Which claims on a listing are testable at all is the subject of our guide to what is on the market.

Buying BPC-157 peptide into the UK and the EU

Search bpc-157 where to buy uk and the results look domestic. Most are not. The regulatory position is straightforward and unchanged: the MHRA has not licensed BPC-157 as a medicine, no EMA marketing authorisation exists, and no pharmacy in either territory can dispense it. Nothing about a British-looking storefront changes that.

The risk sits with the person who placed the order, which is the honest way to put it. We give no guidance on how a shipment is described, declared or routed, and this is not legal advice. If you are subject to anti-doping testing the question is settled before any of the above: the World Anti-Doping Agency prohibits BPC-157 at all times under S0, the category covering substances with no current approval for human therapeutic use.

Where a UK stockist usually sits in the chain

A storefront that quotes in pounds, holds no stock, and dispatches from a US warehouse when an order arrives is a reshipper. That is not automatically a problem, but it breaks the link this page depends on: the certificate you were shown belongs to a lot held by someone else, and the reshipper is rarely in a position to tell you which batch will actually be picked. The test is direct. Ask which lot number will ship and ask for the certificate that carries it. A supplier holding its own stock answers immediately.

The analytical literature on products sold outside regulated channels is worth a look before assuming a listing describes itself accurately. A 2015 study in Drug Testing and Analysis used LC-UV-MS/MS to identify and characterise melanotan II products sold illegally online, a different peptide sold through a similar market structure. The general point survives the change of compound: what a vial contains is an empirical question, and the answer comes from an instrument rather than from a product page.

Grading the evidence behind the molecule

The tendon and soft-tissue findings that make people want to buy this peptide are rat and cell work. The frequently cited 2011 experiment in the Journal of Applied Physiology reported effects on tendon fibroblast outgrowth, survival and migration in cultured cells and a rat model, which is a mechanistic result and not a clinical one. A large share of the wider literature comes from a single research group at the University of Zagreb, and independent replication of the central results is limited. No large human efficacy trial has reported. The first controlled human test is now under way and has not reported: a randomised, double-blind, placebo-controlled Phase 2 in acute grade II hamstring strain, sponsored by Hudson Biotech, began recruiting 120 participants on 2 February 2026 with primary completion estimated no earlier than 14 February 2027 (NCT07437547). On this site the compound grades as preclinical, with that trial pending.

The regulatory picture in the United States moved twice in 2026 and most pages are stale on it: never approved, placed in the FDA's Category 2 in September 2023, removed from that category in April 2026 after the nominations were withdrawn, then narrowly and non-bindingly recommended for the 503A Bulks List by the Pharmacy Compounding Advisory Committee on 23 and 24 July 2026, with no final determination and no listing in 21 CFR 216.23. The full sequence is in our regulatory explainer. None of it changes what you are buying, which is a vial of powder and a document that either describes it or does not.